With positive topline Phase II results and plans to move it into Phase III development, Takeda Pharmaceutical Co. Ltd.’s mezagitamab joins the drug maker’s list of Phase III-ready assets that together provide a glimpse of its diversified development strategy.
Takeda Charges Into Diversification With ITP Win
Results Further Long-Term Strategy
The company announced positive topline results from a Phase II study of mezagitamab and expects to have five programs in Phase III development this fiscal year.
